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Abstract
Ivermectin is a pivotal drug for the control of onchocerciasis and lymphatic filariasis, which is
increasingly identified as a useful drug for the control of other Neglected Tropical Diseases.
Its role in the treatment of soil transmitted helminthiasis through improved efficacy against
Trichuris trichiura in combination with other anthelmintics might accelerate the progress
towards breaking transmission. Ivermectin is a derivative of Avermectin B1, and consists of
an 80:20 mixture of the equipotent homologous 22,23 dehydro B1a and B1b. Pharmacoki-
netic characteristics and safety profile of ivermectin allow to explore innovative uses to fur-
ther expand its utilization through mass drug administration campaigns to improve coverage
rates. We conducted a phase I clinical trial with 54 healthy adult volunteers who sequentially
received 2 experimental treatments using a new 18 mg ivermectin tablet in a fixed-dose
strategy of 18 and 36 mg single dose regimens, compared to the standard, weight based
150–200 μg/kg, regimen. Volunteers were recruited in 3 groups based on body weight.
Plasma concentrations of ivermectin were measured through HPLC up to 168 hours post
treatment. Safety data showed no significant differences between groups and no serious
adverse events: headache was the most frequent adverse event in all treatment groups,
none of them severe. Pharmacokinetic parameters showed a half-life between 81 and 91 h
in the different treatment groups. When comparing the systemic bioavailability (AUC0t and
Cmax) of the reference product (WA-ref) with the other two study groups using fixed doses,
we observed an overall increase in AUC0t and Cmax for the two experimental treatments of
18 mg and 36 mg. Body mass index (BMI) and weight were associated with t1/2 and V/F,
probably reflecting the high liposolubility of IVM with longer retention times proportional to
the presence of more adipose tissue. Systemic exposure to ivermectin (AUC0t or Cmax) was
not associated with BMI or weight in our study. These findings contribute to further under-
stand the pharmacokinetic characteristics of ivermectin, highlighting its safety across differ-
ent dosing regimens. They also correlate with known pharmacokinetic parameters showing
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stable levels of AUC and Cmax across a wide range of body weights, which justifies the strat-
egy of fix dosing from a pharmacokinetic perspective.
Trial registration
ClinicalTrials.gov NCT03173742.
Author summary
Current efforts for the control of poverty-related diseases provide drug treatments
through mass drug administration (MDA) as a key component. Ivermectin is an antipara-
sitary drug which has been used to fight some of these diseases, and millions of treatments
have been distributed with a favorable toxicity profile. The dosing strategy of ivermectin is
based on weight, which in view of the safety characteristics of ivermectin might not be
necessary, while a fix dosing strategy might improve logistics and access to the drug to
those who need it. This study was conducted in healthy adult volunteers in which we com-
pared 3 treatment regimens: the weight-based reference standard versus 2 experimental
regimens of fix-dose 18 and 36 mg using 18 mg tablets. All 54 volunteers received the 3
treatments sequentially. The results confirmed that the fixed-dose regimen (both 18 mg
and 36 mg) are as safe as the standard dosage and could justify the use of fix dosing regi-
mens rather than the current weight based strategy.
Introduction
The control of Neglected Tropical Diseases (NTDs) has in ivermectin (IVM) the most signifi-
cant tool among all the drugs used for morbidity control and interruption of transmision. Due
to its impact on onchocerciasis and lymphatic filariasis (LF), this macrocyclic lactone has been
used in millions of individuals mainly through the Mectizan Donation Program, achieving
goals of breaking transmission in several countries and putting those landmark achievements
in the horizon of several other countries [1–3]. The very basic approach to the use of IVM con-
sists in its distribution to entire communities through annual or biannual mass drug adminis-
tration (MDA) campaigns provided its excellent safety profile [4], whose only significant
severe adverse reaction has been determined by its use in Loa loa infected individuals due to
the life-threatening adverse events in this group [5].
The large experience on the use of IVM in the veterinary world, where it was first intro-
duced in 1981 and the growing perception of its capabilities in human disease since its intro-
duction in 1985 has widened its indications to a growing number of infectious diseases. The
wide spectrum of action of IVM includes treatment of Strongyloides stercoralis, Gnathostoma
spp, Mansonella streptocerca and ectoparasites such as head lice or scabies [1, 6]. Moreover, it
has been evaluated in co-administration with albendazol for the treatment of soil transmitted
helminthiasis (STH) showing an increased efficacy compared to albendazole stand-alone
against Trichuris trichiura [7, 8], therefore increasing the feasibility of achieving transmission
interruption, as shown in modelling exercises [9]. Due to its alternative mechanism of action,
the addition of IVM to a benzimidazole based regimen lowers the threat of emergence of drug
resistance [10], as suggested in modelling studies conducted in veterinary medicine [11]. Fur-
thermore, the recent finding that the endectocide effect of IVM reduces the survival of Anophe-
les mosquitoes that feed on an IVM treated person after a single standard oral dose, supports
Fixed-dose ivermectin pharmacokinetics
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006020 January 18, 2018 2 / 16
members of Chemo Group, which includes
Liconsa, the manufacturer of the study drug and
Exeltis France, the funding source.
the integration of IVM-based interventions for the control of multiple tropical infectious dis-
eases [12, 13].
Along with its favorable pharmacodynamic aspects, the pharmacokinetic characteristics of
IVM also appear to be opening possibilities to expand its use and access. It has rapid oral
absorption, high liposolubility and is widely distributed in the body [14]. Following a standard
oral dose in healthy humans, IVM reaches peak plasma levels at 3.4 to 5 hours; and plasma
half-life has been reported to be 12 to 66 hours [15, 16]. It is metabolized in the liver through
the cytochrome P450 system and excreted almost exclusively in feces [14, 17]. Despite its wide-
spread use, there are relatively few studies on the pharmacokinetics of IVM in humans [18]
and a full understanding of the relationship between drug levels and activity is also missing,
including the mechanisms related to remnant activity beyond time points when significant
drug levels are measured, as has been demonstrated in veterinary and vector-borne diseases
studies [19, 20]
Regardless of its safety profile and pharmacokinetic features, IVM is prescribed for all its
indications in weight (or height) based regimens, which difficult its administration in MDA
interventions and introduces the risk of under-dosing [21]. A fixed and high dose regimen
which takes advantage of the wide therapeutic index of IVM is an attractive alternative for
improving the distribution and therefore potentially increasing coverage rates of treatment
campaigns as has been the case for primaquine in the treatment of malaria [22]. Moreover, a
safe and efficacious fixed-dose IVM in formulations different than the traditional 3 and 6 mg
tablets would be required if co-formulated with other anthelmintics such as albendazole. The
aim of this study was to evaluate the safety and pharmacokinetic profile of two fixed doses of
IVM using a newly developed 18 mg tablet formulation compared to a standard dosing regi-
men at 150–200 μg/kg in healthy adult volunteers.
Methods
Study design
This study was designed to evaluate the safety and pharmacokinetic profile of 3 dosing regi-
mens of IVM in 54 healthy adult volunteers stratified in 3 weight groups in an open-label, ran-
domized, crossover phase I clinical trial performed under fasting conditions. The study was
single dose, three-period, comprising 3 experimental phases of treatment with different doses
of IVM. Each experimental period lasted from at least 12 h prior to drug administration to
+ 168 h post-dose (7 days). The study was carried out at the Centre d’Investigacio´ de Medica-
ments (CIM-Sant Pau) of the Hospital de la Santa Creu i Sant Pau, in Barcelona, Spain and
registered at clinicaltrials.gov (REF NCT03173742).
Study drugs, doses and dosing regimen
The drugs administered were IVM 18 mg, manufactured by Laboratorios Liconsa S.A., Spain
and IVM Revectina 6 mg, manufactured by Abbott Laborato´rios do Brasil Ltda, Brazil [23],
both as immediate-released tablets.
Three groups of 18 healthy volunteers with different weights participated in this trial. All
participants in each group received three sequential treatments with 240 mL of mineral water.
Subjects in Group 1, weighing from 51 to 65 kg, in Group 2, weighing from 66 to 79 kg and in
Group 3, weighing 80 kg received: i) one tablet of IVM 18 mg (FD18), ii) two tablets of IVM
18 mg, 36 mg in total (FD36) and iii) IVM Revectina 200 μg/kg in 6mg tablets (Weight-
adjusted reference treatment: WA-ref) using the following sliding scale: 50 to 64.9 kg 2 tabs, 65
to 79.9 kg 2 ½ tabs, 80 to 94.9 kg 3 tabs, 95 to 109.9 kg 3 ½ tabs and 110 to 115 kg 4 tabs. A
fourteen-day washout period between each dosing was used (Fig 1). The rationale for the
Fixed-dose ivermectin pharmacokinetics
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006020 January 18, 2018 3 / 16
dosing groups was based on the prescription of 2 experimental fixed doses of IVM that provide
an amount of drug per kg of body weight that was up to over 700 μg/kg with a minimum of
150 or 300 μg/kg for individuals of up to 120 kg (Fig 2). At the beginning of the study, the sub-
jects were allocated to a randomization number following a procedure of consecutive assign-
ment following a randomization list generated using Windows SPSS software (IBM Corp.
Released 2013. IBM SPSS Statistics for Windows, version 22.0. Armonk, NY: IBM Corp) in a
balanced way (an equal number of subjects in each treatment sequence).
Sample size
From the coefficients of variation of the truncated AUC obtained (49.75%) from previous
pharmacokinetic studies with ivermectin [15, 16, 24] performed in healthy volunteers, by
applying the formula of Sanford Bolton [25] considering an error of type 1 or α of 0.05 and an
error of type 2 or β of 0.20, the sample size obtained was 50 volunteers. However, we stratified
the volunteers by body weight into 3 groups, (N of 18 volunteers per group, N = 54). Neverthe-
less, the proposed sample size of 18 volunteers per group was within the range cited in several
publications about the pharmacokinetic evaluation of IVM [15, 16, 24] and it was considered
adequate for the analysis of the main objective of the study. In order to avoid the possible
Fig 1. Clinical trial design describing the three different treatment sequences and the wash-out period.
https://doi.org/10.1371/journal.pntd.0006020.g001
Fig 2. Dosing scheme for the 3 treatment arms with the corresponding weight based exposure for the body weight
range of the subjects included in the study. Fixed-dose 18 mg and 36mg with 18 mg tablets and 200μg/kg with 6mg
tablets.
https://doi.org/10.1371/journal.pntd.0006020.g002
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confounding effect of the sex factor, an imbalance of more than 60%, in the male of female
ratio (rounding off to the nearest whole number) was not allowed.
Subjects and clinical assessments
Participants were male and female subjects aged between 18 and 45 years meeting the inclu-
sion criteria: i) No abnormal findings in medical history and physical examination, ii) Normal
laboratory tests (hematology evaluations, blood chemistry and urinalysis), vital signs (systolic
and diastolic blood pressure, heart rate and temperature) and ECG record, iii) Not having par-
ticipated in another clinical trial during the 3 months before starting the current trial and iv)
Not having donated blood during the 8 weeks prior to starting the current trial. Female volun-
teers had to use reliable contraceptive measures not containing hormones. Participants were
asked to abstain from drinking alcoholic, xanthine-containing beverages, St John’s Wort, vita-
mins, herbal remedies and chewing-gum from 48 hours prior to the beginning of the study
until study completion. They also agreed to abstain from beverages or food containing grape-
fruit for 14 days prior to the first study drug administration until study completion. Partici-
pants with prior history of alcohol consumption or use or abuse of recreational drugs,
consumption of stimulating drinks (> 5 cups of coffee, tea, chocolate or cola drinks per day),
smokers or ex-smokers that gave up smoking less than 1 year prior to the study, with history of
allergy, idiosyncrasy or serious adverse events and hypersensitivity to drugs or excipients
included in drugs, positive serology for hepatitis B, C, or for HIV, and those who took any
other medication or medicinal plants in a 15-day period prior to the trial, with history or clini-
cal evidence of chronic diseases, having surgery during the previous 6 months, pregnant or lac-
tating women were excluded. None of the volunteers was at risk of being affected by Loa loa or
other filarial infections.
During the three treatment periods, urine pregnancy test for female subjects and urine
screening for abuse drugs (ethanol, cannabis, cocaine, amphetamines, opiates, benzodiaze-
pines) were performed within the 12 hours before each treatment administration and they
were not discharged until +24 h post-medication. Then they returned to the CIM-Sant Pau at
+36 h, +48 h, +72 h, +120 h, and +168 h post-dose, for blood extractions.
In each period after fasting overnight for 10 h, subjects received the assigned treatment
described above. Fasting continued until +4 h postmedication at which time a standard break-
fast was served, followed by a standard lunch at +7 h and a standard dinner at +10 h postmedi-
cation. During the experimental phase in each period, volunteers were allowed to drink water
ad libitum and eat solids from 4 hours after dosing.
Sample collection and analysis
Nineteen venous samples of 6 mL (2 and 4 mL for IVMB1a and IVMB1b respectively) were col-
lected into EDTA K2 plastic tubes at baseline and at +0.5 h, +1 h, +2 h, +3 h, +3.5 h +4h, +5 h,
+6 h, +8 h, +10 h, +12 h, +16 h, +24 h through a cannula placed in the arm of the volunteer and
at +36 h, +48 h, +72 h, +120 h, and +168 h post-drug administration by direct venipuncture.
Blood samples were centrifuged within 60 minutes after extraction for 10 minutes at 1900 g and
at 4˚C and the resulting plasma samples were separated into two aliquots of 0.4 and 0.3 mL for
IVMB1a and 1.0 and 0.4 mL for IVMB1b respectively that were stored at -20˚C ± 5˚C until
assayed.
Bioanalytical determinations were performed by Anapharm Europe S. L. using a HPLC/
MS/MS technique following a full validated method coded 13ANE-2242V and 13ANE-2243V
for IVMB1a and IVMB1b respectively according to Guideline on bioanalytical method valida-
tion [26], with a limit of quantification of 0.4 ng/mL and 40 pg/mL for IVMB1a and IVMB1b
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respectively and following the Guide for validation of analytical and bioanalytical methods
[27]. Analytical work was performed according to Good Laboratory Practices (GLP).
The calibration curve ranged from 0.40 to 40.00 ng/mL for IVMB1a and from 39.80 to
3980.00 pg/mL for IVMB1b. IVMB1a was extracted by a liquid-liquid procedure with tert-
butyl methyl ether, whereas IVMB1b was extracted with a protein precipitation procedure
with formic acid 1% prepared in acetonitrile and a subsequent liquid-liquid extraction with
dichloromethane. The internal standard for IVMB1a and IVMB1b was doramectin. Within-
run accuracy (at 0.40, 1.20, 100.00, 150.00, 200.00 and 2000.00 ng/mL for IVMB1a and at
44.80, 134.40, 2800.00, 4200.00, 5600.00 and 56000.00 pg/mL IVMB1b) ranged from 100.57–
109.83% to 103.01–110.37% for IVMB1a and IVMB1b, respectively. Between-run precision
was not higher than 5.58% and 10.63% for IVMB1a and IVMB1b, respectively.
Pharmacokinetic analysis
The Per-Protocol population, (defined as all randomized subjects who met the entry criteria,
received all study medication, completed the study and did not present protocol violations)
was used for the pharmacokinetic analysis. Pharmacokinetic parameters were estimated from
the sum of IVMB1a and IVMB1b plasma concentrations–time data by non-compartmental
analysis using Profesional WinNonlin-Pro version 2.1 (Pharsight Corporation, Saint Louis,
MO).
Missing samples were treated as non-reportable concentration. In the case of volunteers
having plasma concentrations at baseline greater that 5% of Cmax (in treatment periods 2 and/
or 3), we performed a sensitivity analysis by adding or substracting this individual from the
analysis in order to evaluate the impact of that volunteer in the pharmacokinetic profile. Cmax
was obtained directly from the plasma concentration–time data. The area under the plasma
concentration–time curve (AUC) to the last time with measurable concentration exceeding
the limit of quantification (Ct) of the drug (AUC0
t) was estimated by applying log/linear trape-
zoidal rule. The terminal plasma elimination half-life (t1/2) was calculated as t1/2 = 0.693/ke,
where ke represents the first-order elimination rate constant associated with the terminal (log
linear) portion of the curve, estimated via linear regression of time versus log concentration.
The apparent volume of distribution (V/F) of IVM was calculated as V/F = D/(keAUC01),
where D is dose and F is bioavailability and AUC extrapolated to infinity (AUC01) was deter-
mined by adding the extrapolated area (Ct/ke) to the AUC0t. Total oral clearance (Cl/F) was
calculated as D/AUC0
t.
Safety and tolerability assessments
The safety population defined as all randomized subjects who took at least one dose of the
study medication was used for safety analyses. Vital signs (systolic/diastolic blood pressure in
decubitus and heart rate) were recorded on each treatment day at baseline and at +0.5 h, + 1h,
+4 h, +10 h, +24 h, +48 h, +120 h, and +168 h post-dose; hematology evaluations, blood chem-
istry, and urianalyses were performed at the screening visit in all subjects and at the end of
each of the three periods.
Moreover, a complete physical examination and ECG were assessed at the screening visit
and at the end of each the three periods. All adverse events observed either by the investigator
or reported by the subjects themselves during the clinical study were also recorded and evalu-
ated by the investigator for severity and relationship to the study drug. The severity of each AE
was graded according to the following categories: mild, moderate, or severe.
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Ethical statement
The study adhered to the updated Declaration of Helsinki [28] and was conducted according
to rules of Good Clinical Practice [29]. Prior to initiation, the study protocol was approved by
an independent ethics committee (Clinical Research Ethics Committee of the Hospital de la
Santa Creu i Sant Pau, in Barcelona, Spain) and the national competent authority (Spanish
Agency for Medicines and Health Care Products, AEMPS, Spain). All subjects provided writ-
ten informed consent to participate in the study after the nature and purpose of the study was
fully explained to them and received stipends for their collaboration.
Statistical analysis
Descriptive statistics were calculated for all pharmacokinetic parameters as well as a compari-
son between treatments were performed for all pharmacokinetic parameters. A comparative
analysis of bioavailability was applied for the parameters determining exposition in extent
[AUC0
t] and rate of absorption [Cmax] without dose correction. Three four-way analysis of
variance (ANOVA) for the crossover design were used to assess the effect of dosage, periods,
sequences, and subjects-within-sequences on the same parameters. For comparison of the
safety and tolerability of IVM between fixed doses (FD18 vs FD36) and between fixed doses
and WA-ref adjusted by body weight for each group, an ANOVA and posterior paired analysis
with contrast was performed for the parameters obtained in the vital signs, ECG, hematology
evaluations, blood chemistry and urianalyses. Additionally, for pooling of all groups, an
ANOVA of 2 factors (ANOVA group and treatment arm) and posterior paired analysis with
contrast was performed for the same parameters.
The incidence of treatment-emergent AEs (TEAEs) was classified by system organ class
and preferred term according to the Medical Dictionary of Regulatory Activities (MedDRA
version 20.0), the relationship to the study drug, and the severity for each dose.
Plasma concentrations over 16 ng/ml are generally considered antimosquitocidal for indi-
viduals receiving IVM [13]. The minimum, maximum, and median time during which partici-
pants had concentrations superior to 16 ng/ml were calculated and compared by means of a
Friedman test an a posterior Wilcoxon test, overall and for each weight group.
Additionally, we explored the statistical association of weight and BMI with the main PK
parameters (AUC0
t, Cmax, V/F, Cl/F and t1/2) by means of an ANCOVA incorporating weight
or BMI as a covariates. All the analysis were carried out by mean of Windows SPSS software
(IBM Corp. Released 2013. IBM SPSS Statistics for Windows, version 22.0. Armonk, NY: IBM
Corp).
Results
Subjects
Study population initially included 27 female and 30 male caucasian volunteers without clini-
cal evidence of laboratory, ECG or vital sign abnormalities. None of the randomized subjects
were smokers. A description of the most important demographic parameters and other base-
line data is shown in Table 1.
Fifty-seven volunteers were included in the study and received at least one dose of study
drug. After recruitment, one volunteer withdrawn due to personal reasons and two were
excluded (one for for a slightly prolonged partial thromboplastin time and the other by proto-
col deviation in treatment administration) and did not complete the study. A total of 54 volun-
teers completed the study (Fig 3).
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Safety
All subjects receiving at least one dose of study drug were included in the safety analysis
(n = 57). No abnormal result or significant differences were found between biochemistry at
baseline and after the administration of IVM in any of the three study arms. A slight decrease
in Haemoglobin (Hb) levels was observed after administration of IVM in the three study arms.
Hb decreased from 142.80 ± 13.8 g/L at the screening to 137.1 ± 13.55 g/L at the end of the
study in the WA-ref (p<0.001), to 136.5 ± 14.51 g/L for FD18 (p<0.001) and to 135.4 ± 12.97
g/L for FD36 (p<0.001). However, no signs or symptoms of anemia were detected in any of
Table 1. Baseline characteristics of study population (n = 57) in the 3 weight strata. BMI: body mass index.
Group Variable N Mean SD Min Max
Group I (51–65 kg)
n = 18
Gender (male/female) 7/11
Age (years) 18 26.83 6.09 19 41
Body weight (kg) 18 58.92 4.01 52 65
Height (cm) 18 165.57 6.83 156 180
BMI (kg/m2) 18 21.55 2.15 18.26 25.67
Group II (66–79 kg)
n = 19
Gender (male/female) 7/12
Age (years) 19 30.32 6.56 22 41
Body weight (kg) 19 71.46 4.01 66 79.50
Height (cm) 19 171.89 6.69 159 184
BMI (kg/m2) 19 24.27 2.08 20.38 26.85
Group III (>80 kg)
n = 20
Gender (male/female) 9/11
Age (years) 20 29.10 6.74 21 41
Body weight (kg) 20 87.87 8.46 80 114
Height (cm) 20 172.85 8.87 158 190
BMI (kg/m2) 20 29.71 4.99 24.38 45.67
https://doi.org/10.1371/journal.pntd.0006020.t001
Fig 3. Group 1, subjects weighing from 51 to 65 kg, Group 2 weighing from 66 to 79 kg and Group 3
weighing 80 kg. Flow diagram of the study.
https://doi.org/10.1371/journal.pntd.0006020.g003
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the study participants. The main electrocardiographic parameters were not affected by the
administration of IVM. Systemic blood pressure measurements were not affected by treatment
administration.
A total of 33 treatment emergent adverse events were reported by 22 subjects who received
at least one dose of the study medication. Eleven adverse events were reported by 10 subjects
after receiving WA-ref, 9 were reported by 9 subjects after receiving FD18 and 13 were
reported by 13 subjects after FD36 (Table 2). No significant association was found between the
distribution of adverse events and the three treatments arms (p = 0.695). The most frequent
adverse event described by study participants was headache (6.02% of the study subjects), fol-
lowed by dysmenorrhea (5.54%), throat pain (1.80%) and diarrhea (1.80%). Of the 33 adverse
events reported, 10 were graded as mild and 23 were graded as moderate. The type and distri-
bution of adverse events by study group are shown in Table 3. Fifteen adverse events were con-
sidered possibly related to the investigational products and 18 not related to the investigational
products. It was necessary to administer concomitant medication on 14 subjects due to
appearance of adverse events (Table 2).
Pharmacokinetics
The initial analysis of plasma concentrations for IVM showed that one participant presented
baseline levels of IVMB1a above 5% of Cmax in period 2, 4 participants presented baseline lev-
els above 5% of Cmax of IVMB1b in period 2 and 2 participants presented baseline levels above
5% of Cmax of IVMB1b in period 3. A sensitivity analysis was conducted to evaluate if the
absence of these 5 subjects with the pre-dose value greater than 5% of Cmax value had implica-
tions in the main PK parameters. Since the results were not significantly altered, we present
the main results of the study including all 54 participants.
The pharmacokinetic parameters of IVM in the three study groups are shown in Table 4.
Fig 4 shows the mean IVM plasma concentrations in the three treatment arms.
The parameters related with drug exposure (AUC0
t and Cmax) showed a high interindivid-
ual coefficient of variation (CV) (CV = 37.4% and CV = 32.5%) and intraindividual variability
(CV = 39.6% and CV = 33.2%) respectively. When comparing the systemic bioavailability
(AUC0
t and Cmax) of WA-ref with the other two study groups using fixed doses, we observed
an overall increase in AUC0
t of 2.9% for FD18 and a 74.44% increase for FD36. These higher
values were observed in Cmax as well, showing a similar increase of 4.7% of the systemic
Table 2. Distribution of adverse events by frequency and treatment arm. WA-ref: weight adjusted reference group (200 μg/kg), FD18: fixed-dose 18 mg, FD36: fixed-
dose 36 mg).
Treatment
Before treatment (N = 57) WA-ref
(N = 54)
FD18
(N = 55)
FD36
(N = 57)
Total
(N = 57)
All reported adverse events 1 (1.8%) 1 10 (18.5%) 11 9 (16.4%) 9 13 (22.8%) 13 23(40.4%) 34
Treatment-emergent adverse events (TEAEs) n.a. 10 (18.5%) 11 9 (16.4%) 9 13 (22.8%) 13 22 (38.6%) 33
Relationship Study-drug related TEAEs n.a. 7 (13.0%) 8 2 (3.6%) 2 5 (8.8%) 5 9 (15.8%) 15
Not study-drug related TEAEs n.a. 3 (5.6%) 3 7 (12.7%) 7 8 (14.0%) 8 17 (29.8%) 18
Severity Mild AEs 1 (1.8%) 1 3 (5.5%) 4 2 (3.6%) 2 4 (7.0%) 4 10 (17.5%) 11
Mild TEAEs n.a. 3 (5.5%) 4 2 (3.6%) 2 4 (7.0%) 4 9 (15.8%) 10
Moderate TEAEs n.a. 7 (13.0%) 7 7 (12.7%) 7 9 (15.8%) 9 23 (40.4%) 23
AEs requiring therapy 1 (1.8%) 1 7 (13.0%) 7 7 (12.7%) 7 7 (12.3%) 7 14 (24.6%) 22
Serious TEAEs (SAEs) n.a. 0 (0) 0 0 (0) 0 0 (0) 0 0 (0) 0
TEAEs leading to dose withdrawal n.a. 0 (0) 0 0 (0) 0 1 (1.8%) 0 1 (1.8%) 1
https://doi.org/10.1371/journal.pntd.0006020.t002
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bioavailability for FD18 and a 80.69% increase for FD36. The analysis of the relationship
(ANCOVA) between IVM PK parameters with BMI and weight indicates that individuals with
high BMI and weight present higher V/F and t1/2. However, no significant association was
found between weight and BMI with Cmax and AUC0
t (Table 5).
The median time (hours) which the participants presented plasma IVM levels above those
described as the lethal concentration 50 (LC50) against Anopheles gambiae s.s. (>16 ng/ml) was
8 h for WA-ref, 8 h for FD18 and 14 h for FD36 (p<0.001).
Discussion
We report in this study safety and pharmacokinetic results of an alternative dosing regimen
for IVM. These results are of particular relevance for public health interventions based on pre-
ventive chemotherapy through MDA of anthelmintics as those used for onchocerciasis and LF
and under study for other NTDs like STH and scabies, as well as malaria [9, 30, 31]. This study
provides the first pharmacokinetic and safety data of a formulation of IVM in 18 mg tablets,
which adds further logistical advantages for fixed dosing as proposed in this study and sets the
pharmaceutical conditions for an eventual co-formulation with other anthelmintics like alben-
dazole for the control of LF, Trichuris trichiura and S. stercoralis in areas where these species
are found among the prevalent STH.
Safety data was consistent with previous studies regarding the lack of significant adverse
events even at the highest doses uses in this study (36 mg) which in the lowest weight group
(51 to 65 kg) providing doses of up to 700 mcg/kg [16, 32, 33]. Changes in Hb observed
through the study, even in the control group treated with usual dosing, might be explained by
the frequent blood draws although further studies might be needed. However, these hemato-
logic results were not found in other smaller studies using IVM at doses up to 2000 mcg/kg in
healthy volunteers or 800 mcg/kg in individuals infected with O. volvulus [16, 34]. Although
IVM was very well tolerated, 14 participants received treatment to control adverse events that
Table 3. Distribution of adverse events by treatment arm. WA-ref: weight adjusted reference group (200 μg/Kg),
FD18: fixed-dose 18 mg, FD36: fixed-dose 36 mg).
Adverse event WA-ref
(n = 54)
FD18
n = 55
FD36
n = 57
Total
(n = 166)
n % n % n % n %
Headache 5 9.3 2 3.6 3 5.3 10 6.02
Dizziness 1 1.9 - - - - 1 0.60
Dysmenorrhea 1 1.9 3 5.5 1 1.8 5 >5.54
Vaginal candidiasis - - 1 1.8 - - 1 >0.60
Throat pain - - 1 1.8 2 3.5 3 >1.80
Cold - - 1 1.8 2 3.5 3 >1.80
Gastroenteritis - - 1 1.8 - - 1 >0.60
Nausea - - - - 1 1.8 1 >0.60
Tooth pain - - - - 1 1.8 1 >0.60
Back pain 1 1.9 - - 1 1.8 2 >1.20
Abdominal pain 1 1.9 - - - - 1 >0.60
Diarrhea 2 3.7 - 1 1.8 3 >1.80
Prolongued coagulation time - - - 1 1.8 1
0.60
% calculated regarding to total subjects under each treatment
n resulting by the addition of number of subjects under each treatment
https://doi.org/10.1371/journal.pntd.0006020.t003
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Table 4. PK parameters of IVM for entire study population and by the 3 weight strata. WA-ref: weight adjunted reference group (200 μg/kg), FD18: fixed-dose 18 mg,
FD36: fixed-dose 36 mg).
Parameters
(raw data)
WA-ref FD18 FD36
Arithmetic mean (SD)
Median [min- max]
Arithmetic mean (SD)
Median [min- max]
Arithmetic mean (SD)
Median [min- max]
All study groups (n = 54)
AUC0
t (ngh/mL) 860.13 (384.13)
830.09 [247.01–1795.24]
885.92 (514.23)
792.60 [154.49–2340.65]
1500.40 (838.40)
1440.83 [353.68–3908.27]
AUC0
1 (ngh/mL) 1087.81 (505.16)
1013.01 [323.20–2245.68]
1132.50 (684.05)
1057.84 [179.36–3065.69]
1906.68 (1136.50)
1629.30 [410.34–5487.41]
Cmax (ng/mL) 43.19 (18.11)
44.52 [22.28–77.22]
45.23 (24.29)
38.09 [11.17–103.48]
78.04 (43.11)
65.49 [20.91–199.97]
tmax 4.15 (1.20)
4.00 [2.00–8.00]
4.33 (1.94)
4.00 [2.00–16.00]
4.11 (1.07)
4.00 [2.00–8.00]
t1/2 (h) 80.66 (33.33)
76.73 [24.90–177.28]
80.98 (48.51)
67.36 [18.04–333.76]
90.56 (58.17)
75.44 [30.37–372.02]
V/F (L) 1822.29 (857.21)
1592.81 [627.07–4321.88]
2266.20 (1215.22)
2012.66 [704.01–6719.59]
3000.97 (1677.28)
2747.62 [798.15–8063.24]
Cl/F(L/h) 17.31 (9.16)
15.29 [5.34–46.41]
24.40 (19.14)
17.02 [5.87–100.36]
27.33 (17.71)
22.10 [6.56–87.73]
Group 1 (n = 18)
AUC0
t (ngh/mL) 866.62 (435.52)
834.27 [293.95–1795.24]
1112.80 (547.60)
1077.67 [393.25–2340.65]
1787.67 (930.102)
1625.34 [353.68–3387.34]
AUC0
1 (ngh/mL) 1040.85 (521.02)
980.15 [353.27–2245.68]
1322.69 (707.92)
1265.90 [495.75–3065.69]
2230.69 (1362.14)
1857.52 [410.34–5487.41]
Cmax (ng/mL) 44.76 (19.47)
45.33 [16.12–86.42]
56.09 (24.73)
52.19 [21.62–103.48]
96.20 (52.11)
71.80 [14.16–99.99]
tmax 4.08 (0.96)
4.00 [2.00–6.00]
4.08 (1.30)
3.50 [2.00–8.00]
4.19 (0.94)
4.00 [3.00–6.00]
t1/2 (h) 68.18 (34.43)
59.15 [24.90–177.28]
66.85 (22.23)
62.77 [28.00–105.46]
84.63 (75.13)
65.55 [30.37–372.02]
V/F (L) 1272.55 (595.04)
1209.17 [627.07–2967.48]
1581.69 (818.77)
1317.25 [704.01–3528.47]
2277.92 (1129.88)
2356.62 [798.15–3844.33]
Cl/F(L/h) 15.01 (8.70)
12.26 [5.34–33.97]
17.73 (9.36)
14.23 [5.87–36.31]
24.40 (19.06)
19.38 [6.56–87.73]
Mean time above 16ng/mL (h) 10 10 22
Group 2 (n = 18)
AUC0
t (ngh/mL) 778.37 (333.93)
675.74 [247.01–1571.48]
711.90 (447.43)
639.94 [169.55–1851.18]
1298.22 (813.86)
1341.78 [499.78–3908.27]
AUC0
1 (ngh/mL) 963.30 (401.19)
878.59 [323.20–1842.72]
890.81 (530.21)
806.42 [223.42–2298.88]
1656.78 (1053.15)
1609.95 [569.29–4655.96]
Cmax (ng/mL) 38.18 (16.68)
39.34 [13.86–73.59]
37.94 (22.55)
31.72 [11.17–90.81]
65.39 (34.53)
65.49 [21.97–144.45]
tmax 4.25 (1.57)
4.00 [3.00–8.00]
4.17 (1.21)
3.75 [3.00–8.00]
3.64 (0.89)
3.50 [2.00–5.00]
t1/2 (h) 77.46 (26.78)
76.73 [35.46–126.80]
75.32 (30.56)
64.49 [31.21–131.04]
91.77 (56.18)
79.47 [32.43–271.77]
V/F (L) 1978.44 (890.34)
2051.55 [814.86–3963.29]
2712.47 (1383.54)
2403.01 [1011.58–6719.59]
3488.51 (1846.32)
3230.07 [837.49–7101.50]
Cl/F(L/h) 18.80 (9.73)
17.08 [8.14–46.41]
29.44 (20.53)
22.44 [7.83–80.57]
30.73 (17.71)
22.36 [7.73–63.24]
Mean time above 16ng/mL (h) 8 8 14
Group 3 (n = 18)
AUC0
t (ngh/mL) 935.41 (381.72)
862.69 [376.98–1641.39]
833.05 (484.58)
792.60 [154.49–1706.92]
1415.33 (725.01)
1456.71 [433.14–2858.74]
(Continued)
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were mostly to improve mild headache, common in participants of phase I trials after depriva-
tion of caffeine and other substances. At the same time that fixed and higher doses of IVM
proved to have an excellent safety profile in our study, higher systemic exposure (AUC0
t
increased approximately 65% for FD36) of plasma IVM were achieved overall among study
participants. Although no efficacy evaluation has been done, similar or higher efficacy is
expected against the common pathogens targeted by IVM, while keeping a good safety profile
and facilitating delivery of the drug. As expected, higher levels of AUC0
t and Cmax were found
in participants of group 1, compared to the heavier group of participants in group 3 (FD36).
These differences in systemic exposure among participants having different weights might
Table 4. (Continued)
Parameters
(raw data)
WA-ref FD18 FD36
Arithmetic mean (SD)
Median [min- max]
Arithmetic mean (SD)
Median [min- max]
Arithmetic mean (SD)
Median [min- max]
AUC0
1 (ngh/mL) 1259.27 (559.71)
1153.64 [524.27–2235.71]
1184.00 (757.37)
1128.59 [179.36–2606.35]
1832.58 (937.65)
1677.87 [532.32–3296.75]
Cmax (ng/mL) 46.64 (17.98)
44.52 [22.28–80.61]
41.65 (22.91)
37.08 [12.54–101.36]
72.52 (36.54)
75.16 [20.91–132.46]
tmax 4.11 (1.05)
3.75 [3.00–6.00]
4.75 (2.98)
4.00 [3.00–16.00]
4.5 (1.21)
4.50 [3.00–8.00]
t1/2 (h) 96.33 (33.55)
100.47 [31.54–148.23]
100.78 (72.43)
77.67 [18.04–333.76]
95.30 (41.05)
97.15 [36.35–185.58]
V/F (L) 2215.89 (796.42)
2065.75 [1346.79–4321.88]
2504.44 (1119.11)
2438.91 [847.94–4705.04]
3236.49 (1794.78)
2790.83 [1119.26–8063.24]
Cl/F(L/h) 18.12 (9.09)
16.14 [8.25–34.33]
26.04 (23.57)
15.97 [6.91–100.36]
26.86 (16.72)
21.54 [10.92–67.63]
Mean time above 16ng/mL (h) 10 8 14
https://doi.org/10.1371/journal.pntd.0006020.t004
Fig 4. Mean IVM plasma concentration profiles in 54 individuals exposed sequentially in random order to the 3
treatment arms. Insert describe details of the time points within the initial 36 hours. WA-ref: weight adjusted
reference group (200 μg/kg), FD18: fixed-dose 18 mg, FD36: fixed-dose 36 mg).
https://doi.org/10.1371/journal.pntd.0006020.g004
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have implications on the efficacy of ivermectin, potentially achieving higher cure rates in those
patients with lower weight.
Values of AUC0
t and Cmax at the three dose studied are consistent with linear behavior pre-
viously reported by Guzzo et al. with single doses of up to 120 mg [16]. Pharmacokinetic
parameters related with drug exposure in magnitude (AUC0
t, AUC0
1) and rate (Cmax) showed
a high inter and intra individual variability, as reported by other authors [15, 16, 24, 35]. The
absorption parameter tmax is comparable to that reported in other studies in healthy volunteers
[15, 16, 35]. Disposition parameters (V/F and Cl/F) are rarely reported in IVM pharmacoki-
netic studies in healthy volunteers. However, the values obtained in our study for Cl are in the
range from what has been previously reported from 12 to 30 L/h [36][37].
It has been recently suggested that an increased drug variability associated with suboptimal
drug concentrations may have implications on the development of IVM resistance [11]. How-
ever, this data is based in modeling studies in veterinary medicine, and still more studies are
needed to confirm this hypothesis. The strategy proposed in this study is not only based in a
fixed-doses of IVM but also is based in the use of a high dose, ranging from 200 mcg/kg for
those weighting 90 kg to 360 mcg/kg for those weighting 50 kg. Thus, we ensure that patients
do not receive lower doses of the drug, and most of them receive a superior dose of IVM.
Most notably, elimination half life was long enough to still be detectable at significant levels
(5% of the Cmax) after the 14-day wash-out period in 5 cases, which although proved not to
affect the analysis, highlights the persistence of IVM in plasma in some participants. The elimi-
nation half life ranged between 60 to 100 hours in the different weight groups, with increasing
values in the individuals with higher BMI and weight probably reflecting the high liposolubility
of IVM with longer retention times proportional to the presence of more adipose tissue; an
explanation also consistent with the finding of longer half lifes in females than in males
reported by other authors [38][14]. Our findings reveal longer half lifes of IVM than other
studies reporting values from 12 to 28 h in healthy volunteers, [36] [16][23] However, this
could be expIained due to the fact that other authors reported studies with shorter follow-up
periods and detectable IVM levels at the latest timepoints (56 and 60 hours) [36][16]
The use of IVM for the different indications for which it has a demonstrated clinical useful-
ness has dosing strategies that in all instances are based on weight based dosing. Although
dose finding experiments have identified the appropriate dosing like in onchocerciasis, where
doses higher than 150 mcg/kg appear to have no increments in efficacy (neither toxicity) [32],
there are no target plasma drug levels or adequate markers of efficacy. A potential exception is
being attempted on the benefits of IVM as a mosquitocidal drug for the control of malaria,
where a lethal concentration 50 (LC50) against Anopheles gambiae s.s. has been estimated at
15.9 ng/ml [13]. In our study, those concentrations were maintained for 8 hours in the WA-ref
and FD18 and for 14 hours in the FD36 group. Strategies are currently being evaluated to
Table 5. Effect of BMI and weight in PK parameters.
Parameters
All study groups
(n = 54)
BMI (p-value) Weight (p-value)
t1/2 <0.001 0.001
V/F <0.001 0.001
Cl/F 0.902 0.461
Cmax 0.365 0.115
AUC0
t 0.501 0.288
ANCOVA with BMI and Weight as covariates.
https://doi.org/10.1371/journal.pntd.0006020.t005
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mantain IVM concentrations in human blood at mosquitocidal levels [39]. Our proposal of
using high and fixed dose of IVM could be helpful to prolong IVM concentrations at levels
that could have impact on Anopheles mosquitoes, although probably combined with other
strategies, such as increasing the drug administration to multiple-days regimens [40]
The limitations of this study include the healthy, non-infected status of the volunteers;
although this limitation might not be relevant based on a previous study showing no differ-
ences in PK parameters between O. volvulus infected individuals and controls [35]. Whether
the same applies for individuals infected with gut-dwelling parasites is currently unknown.
Another limitation is the use of a different IVM for the reference group rather than the widely
used Mectizan donated by Merck, which is used in the large majority of MDA programs. How-
ever, the Abbott labs IVM used in this study is the reference IVM product in Brazil [23].
In conclusion, the administration of IVM in a fixed dosing strategy with 18 mg or 36 mg is
as safe as the reference product adjusted by weight, adding a potential benefit due to the
increased systemic exposure to the drug particularly in low weight adult individuals. More-
over, the fixed dose regimen offers a logistical advantage for the deployment of large MDA
interventions aiming at the control and interruption of transmission of NTDs, and facilitates
the co-administration with other antihelmintics prescribed this way, like albendazole or
mebendazole. Further studies evaluating these concepts in pediatric populations and infected
individuals, as well as clinical trials with efficacy endpoints are warranted.
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